Results of research for the assessment of medical innovations’ value at an early phase of development in the Netherlands

22

Sep 2021

In August 2021, the Dutch Healthcare Institute (ZIN) published the results of research for the assessment of the value of medical innovations at an early phase of development. The Radboud university medical center was commissioned by the ZIN to investigate this question based on a case study for Anatomy Projector. The objective of the research was to answer the question of how the value of medical innovation is explored and expressed in an early phase, i.e., before market access.

The Anatomy Projector is a medical device developed in Radboud university medical center that projects anatomical structures on a patient body through augmented reality. This innovation resulted from surgeons' experience that the established procedure of breast reconstruction surgery was suboptimal.

During the research, it was explored which clinical and social values ​​the manufacturer and other involved stakeholders should outline in medical innovations. The findings from this case were discussed with seven Dutch innovation initiatives (Brabant Development Company, Health Innovation Netherlands, Innovative Medical Devices Initiative, LifeSciences@Work, Dutch Research Council, Radboudumc Health Innovation Labs, and Healthcare Innovation Center). The report can stimulate innovators to explore the value of their innovation at the early stage of development and to involve supporting initiatives in this exploration. It will facilitate better guidance and compatibility with the Dutch medical innovation ecosystem.

This research is part of a series of exploratory studies into the introduction of medical innovations in Dutch healthcare practice.

The full details in Dutch can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

25

Mar 2022

On March 4, 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced three projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a new minimally invasive endoscopy-guided surgery in patients with spontaneous cerebral hemorrhage, oral immunotherapy in children to cure a food allergy and cutting the diaphragm band in chronic abdominal complaints.

Read more

18

Feb 2022

Dutch Organization for Health Research and Development, ZonMw awarded eight projects under the "Healthcare Evaluation and Appropriate Use" program, including two projects for geriatric care, two projects for cancer, per one project for cardiovascular, neurovascular, and dermatology care.

Read more

08

Feb 2022

Dutch Healthcare Institute (ZIN) has issued a Pilot Horizon Scan of 39 new diabetes-related MedTech products that are expected on the Dutch market in 2022 or 2023. Patients with diabetes could benefit significantly from the use of these devices. However, available data on their effectiveness and efficiency is limited.

Read more

17

Jan 2022

Dutch Healthcare Authority (NZa) has issued a draft release of the DRG package for 2023, including a new procedure code for intermittent pneumatic compression therapy, a new diagnosis code for guidance in early pregnancy after a fertility program, and several new DRGs for pediatric palliative care, lymphovenous anastomosis surgery and light therapy in inflammatory dermatoses.

Read more

03

Jan 2022

The Dutch Organization for Health Research and Development (ZonMw) will accept applications for subsidies under the "Early Detection" sub-program until March 8, 2022. This scheme is intended for upscaling screening programs or population screening.

Read more